# V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

> **NCT00109343** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1027 (actual)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** Comparator: ProQuad™ (V221)
- **BIOLOGICAL:** Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)

## Key facts

- **NCT ID:** NCT00109343
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 1027 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109343, "V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00109343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*